Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks

Stock Research Monitor: TPIV, VCEL, and VRTX

LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration. On Tuesday, July 24, 2018, US markets sawsevenout of nine sectors finishing the day ingreen and two in red. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 7,840.77, down 0.01%; the Dow Jones Industrial Average edged 0.79% higher, to finish at 25,241.94; and the S&P 500 closed at 2,820.40, up 0.48%. This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: TapImmune Inc. (NASDAQ: TPIV), Vericel Corp. (NASDAQ: VCEL), Viking Therapeutics Inc. (NASDAQ: VKTX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

TapImmune

On Tuesday, shares in Jacksonville, Florida headquartered TapImmune Inc. recorded a trading volume of 475,071 shares. The stock ended the session 16.86% lower at $7.84. The Company's shares have gained 181.00% over the previous three months and 130.59% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.37% and 79.63%, respectively. Moreover, shares of TapImmune, which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, have a Relative Strength Index (RSI) of 41.74. Get the full research report on TPIV for free by clicking below at:

www.wallstequities.com/registration/?symbol=TPIV

Vericel

Cambridge, Massachusetts headquartered Vericel Corp.'s stock closed the day 2.88% higher at $10.70 with a total trading volume of 1.57 million shares, which was above their three months average volume of 1.23 million shares. The Company's shares have advanced 219.40% over the last twelve months. The stock is trading above its 200-day moving average by 24.06%. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs, have an RSI of 49.72.

On July 16^th, 2018, research firm Ladenburg Thalmann upgraded the Company's stock rating from ‘Neutral' to ‘Buy'. Access the free research report on VCEL now by signing up at:

www.wallstequities.com/registration/?symbol=VCEL

Viking Therapeutics

Shares in San Diego, California headquartered Viking Therapeutics Inc. recorded a trading volume of 2.16 million shares. The stock ended yesterday's trading session 3.61% lower at $10.67. The Company's shares have advanced 158.98% over the previous three months and 819.83% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 18.08% and 94.81%, respectively. Furthermore, shares of Viking Therapeutics, which focuses on the development of novel therapies for metabolic and endocrine disorders, have an RSI of 57.97.

On July 20^th, 2018, research firm SunTrust initiated a 'Buy' rating on the Company's stock, with a target price of $14 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VKTX at:

www.wallstequities.com/registration/?symbol=VKTX

Vertex Pharmaceuticals

Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Tuesday's session 0.94% lower at $174.88 with a total trading volume of 1.69 million shares, which was above their three months average volume of 1.65 million shares. The Company's shares have advanced 12.34% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 8.85% and 11.40%, respectively. Additionally, shares of Vertex Pharma, which develops medicines for serious diseases, have an RSI of 57.53. Aspiring Member, please take a moment to register below for your free research report on VRTX at:

www.wallstequities.com/registration/?symbol=VRTX

Wall St.Equities:

Wall St. Equities (WSE) producesregular sponsored and non-sponsored reports, articles, stock market blogs, andpopular investment newsletters covering equities listed on NYSE and NASDAQ andmicro-cap stocks. WSE has two distinct and independent departments. Onedepartment produces non-sponsored analyst certified content generally in theform of press releases, articles and reports covering equities listed on NYSEand NASDAQ and the other produces sponsored content (in most cases not reviewedby a registered analyst), which typically consists of compensated investmentnewsletters, articles and reports covering listed stocks and micro-caps. Suchsponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directlyor indirectly; for producing or publishing this document.

PRESS RELEASEPROCEDURES:

The non-sponsored content containedherein has been prepared by a writer (the "Author") and is factchecked and reviewed by a third-party research service company (the"Reviewer") represented by a credentialed financial analyst [forfurther information on analyst credentials, please email info@wallstequities.com.Rohit Tuli, a CFA® charterholder (the "Sponsor"), providesnecessary guidance in preparing the document templates. The Reviewer hasreviewed and revised the content, as necessary, based on publicly availableinformation which is believed to be reliable. Content is researched, writtenand reviewed on a reasonable-effort basis. The Reviewer has not performed anyindependent investigations or forensic audits to validate the informationherein. The Reviewer has only independently reviewed the information providedby the Author according to the procedures outlined by WSE. WSE is not entitledto veto or interfere in the application of such procedures by the third-partyresearch service company to the articles, documents or reports, as the case maybe. Unless otherwise noted, any content outside of this document has noassociation with the Author or the Reviewer in any way.

NOWARRANTY

WSE, the Author, and the Reviewer arenot responsible for any error which may be occasioned at the time of printingof this document or any error, mistake or shortcoming. No liability is acceptedwhatsoever for any direct, indirect or consequential loss arising from the useof this document. WSE, the Author, and the Reviewer expressly disclaim anyfiduciary responsibility or liability for any consequences, financial orotherwise arising from any reliance placed on the information in this document.Additionally, WSE, the Author, and the Reviewer do not (1) guarantee theaccuracy, timeliness, completeness or correct sequencing of the information, or(2) warrant any results from use of the information. The included informationis subject to change without notice.

NOT ANOFFERING

This document is not intended as anoffering, recommendation, or a solicitation of an offer to buy or sell thesecurities mentioned or discussed, and is to be used for informational purposesonly. Please read all associated disclosures and disclaimers in full beforeinvesting. Neither WSE nor any party affiliated with us is a registeredinvestment adviser or broker-dealer with any agency or in any jurisdictionwhatsoever. To download our report(s), read our disclosures, or for moreinformation, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, orcomments reach out to us directly. If you're a company,we are covering and wish to no longer feature on our coverage list contact usvia email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Fridayat:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, ShawCenter Singapore 228

CFA® and Chartered FinancialAnalyst® are registered trademarks owned by CFA Institute.

SOURCE:Wall St. Equities